Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb, it is currently under development by Biohaven Pharmaceuticals.
New Haven, CT, United States.
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Biohaven Pharmaceuticals is implementing good security practices.
Read more about the latest issues in cybersecurity
In cybersecurity, an attack vector is a path or means by which an attacker can gain unauthorized ...
WannaCry is a ransomware cryptoworm cyber attack that targets computers running the Microsoft ...
Compare Biohaven Pharmaceuticals's security performance with other companies